Flavocoxid, a nutraceutical approach to blunt inflammatory conditions

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Bitto, Alessandra ^a   Squadrito, Francesco ^a   Irrera, Natasha ^a   Pizzino, Gabriele ^a   Pallio, Giovanni ^a   Mecchio, Anna ^a   Galfo, Federica ^a   Altavilla, Domenica ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYTOKINE; FLAVOCOXID; FLAVONOID; NUTRACEUTICAL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG; ARACHIDONATE 5 LIPOXYGENASE; CATECHIN; DRUG COMBINATION; NONSTEROID ANTIINFLAMMATORY AGENT;

ACACIA CATECHU; ARACHIDONIC ACID METABOLISM; ARTHRITIS; CHRONIC DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCUTELLARIA BAICALENSIS; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; ACACIA; ANIMAL; CHEMISTRY; DRUG COMBINATION; METABOLISM; OSTEOARTHRITIS;

ACACIA CATECHU; ARECA CATECHU; SCUTELLARIA; SCUTELLARIA BAICALENSIS;

ACACIA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; CATECHIN; DRUG COMBINATIONS; HUMANS; INFLAMMATION; OSTEOARTHRITIS; SCUTELLARIA BAICALENSIS;

EID: 84930617384     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/790851     Document Type: Review

References (46)

1. S. Bengmark, "Acute and "chronic" phase reaction-A mother of disease, " ClinicalNutrition, vol. 23, no. 6, pp. 1256-1266, 2004.
2. 2-isoprostanes in inflammation and oxidative stress related pathology, "Molecules and Cells, vol. 30, no. 5, pp. 383-391, 2010.
3. T. Lawrence and D.W. Gilroy, "Chronic inflammation: A failure of resolution?" International Journal of Experimental Pathology, vol. 88, no. 2, pp. 85-94, 2007.
4. E. Middleton Jr., C. Kandaswami, and T. C.Theoharides, "The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer, " Pharmacological Reviews, vol. 52, no. 4, pp. 673-751, 2000.
5. D. Ray, K. Sharatchandra, and I. S. Thokchom, "Antipyretic, antidiarrhoeal, hypoglycaemic and hepatoprotective activities of ethyl acetate extract of Acacia catechu Willd. in albino rats, " Indian Journal of Pharmacology, vol. 38, no. 6, pp. 408-413, 2006.
6. N. Sawangjaroen and K. Sawangjaroen, "The effects of extracts fromanti-diarrheicThaimedicinal plants on the in vitro growth of the intestinal protozoa parasite: blastocystis hominis, " Journal of Ethnopharmacology, vol. 98, no. 1-2, pp. 67-72, 2005.
7. L. Tang, W. Wei, and X. Wang, "Effects and mechanisms of catechin for adjuvant arthritis in rats, " Advances inTherapy, vol. 24, no. 3, pp. 679-690, 2007.
8. T. C. Chou, L. P. Chang, C. Y. Li, C. S. Wong, and S. P. Yang, "The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia, " Anesthesia and Analgesia, vol. 97, no. 6, pp. 1724-1729, 2003.
9. C.-P. Chung, J.-B. Park, and K.-H. Bae, "Pharmacological effects of methanolic extract fromthe root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast, " PlantaMedica, vol. 61, no. 2, pp. 150-153, 1995.
10. H. P. Kim, K. H. Son, H. W. Chang, and S. S. Kang, "Antiinflammatory plant flavonoids and cellular actionmechanisms, " Journal of Pharmacological Sciences, vol. 96, no. 3, pp. 229-245, 2004.
11. P. Cheng, Y. Lee, Y.Wu, T. Chang, J. Jin, and M. Yen, "Protective effect of baicalein against endotoxic shock in rats in vivo and in vitro, " Biochemical Pharmacology, vol. 73, no. 6, pp. 793-804, 2007.
12. B. Q. Li, T. Fu, W.-H. Gong et al., "The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines, " Immunopharmacology, vol. 49, no. 3, pp. 295-306, 2000.
13. B. Q. Li, T. Fu, Y. Dongyan, J. A. Mikovits, F. W. Ruscetti, and J. M. Wang, "Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry, " Biochemical and Biophysical Research Communications, vol. 276, no. 2, pp. 534-538, 2000.
14. B. Li, T. Fu, Y. Yan, N.W. Baylor, F. W. Ruscetti, and H. Kung, "Inhibition ofHIV infection by Baicalin-Aflavonoid compound purified fromChinese herbalmedicine, " Cellular andMolecular Biology Research, vol. 39, no. 2, pp. 119-124, 1993.
15. T. Nagai, R. Moriguchi, Y. Suzuki, T. Tomimori, and H. Yamada, "Mode of action of the anti-influenza virus activity of plant flavonoid, 5, 7, 4-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis, " Antiviral Research, vol. 26, no. 1, pp. 11-25, 1995.
16. W. Chang, Z. Shao, J. Yin et al., "Comparative effects of flavonoids on oxidant scavenging and ischemia-reperfusion injury in cardiomyocytes, " European Journal of Pharmacology, vol. 566, no. 1-3, pp. 58-66, 2007.
17. Z. Shao, C. Li, T. L. VandenHoek et al., "Extract fromScutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes, " Journal of Molecular and Cellular Cardiology, vol. 31, no. 10, pp. 1885-1895, 1999.
18. Z. Shao, T. L. Vanden Hoek, Y. Qin et al., "Baicalein attenuates oxidant stress in cardiomyocytes, " American Journal of Physiology- Heart andCirculatoryPhysiology, vol. 282, no. 3, pp.H999- H1006, 2002.
19. D. Y. Zhang, J. Wu, F. Ye et al., "Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis, " Cancer Research, vol. 63, no. 14, pp. 4037-4043, 2003.
20. T. Kumagai, C. I. Müller, J. C. Desmond, Y. Imai, D. Heber, and H. P. Koeffler, "Scutellaria baicalensis, a herbal medicine: Anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines, " Leukemia Research, vol. 31, no. 4, pp. 523-530, 2007.
21. B. Q. Li, T. Fu, W. Gong et al., "The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines, " Immunopharmacology, vol. 49, no. 3, pp. 295-306, 2000.
22. A. Bitto, L. Minutoli, A. David et al., "Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis, " Critical Care, vol. 16, article R32, no. 1, 2012.
23. B. P. Burnett, Q. Jia, Y. Zhao, R. M. Levy, and S. Chen, "A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenaseto reduce inflammation, " Journal of Medicinal Food, vol. 10, no. 3, pp. 442-451, 2007.
24. B. P. Burnett, A. Bitto, D. Altavilla, F. Squadrito, R. M. Levy, and L. Pillai, "Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant, " Mediators of Inflammation, vol. 2011, Article ID385780, 11 pages, 2011.
25. O. Vardeny and S. D. Solomon, "Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk, " Cardiology Clinics, vol. 26, no. 4, pp. 589-601, 2008.
26. J. Martel-Pelletier, D. Lajeunesse, P. Reboul, and J. Pelletier, "Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs, " Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 501-509, 2003.
27. J. T. Mao, I. Tsu, S. M. Dubinett et al., "Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide, " Clinical Cancer Research, vol. 10, no. 20, pp. 6872-6878, 2004.
28. K. D. Rainsford, "Leukotrienes in the pathogenesis of NSAIDinduced gastric and intestinal mucosal damage, " Agents and Actions, vol. 39, pp. C24-C26, 1993.
29. D. Altavilla, F. Squadrito, A. Bitto et al., "Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts proinflammatory phenotype activation in endotoxin-stimulated macrophages, " British Journal of Pharmacology, vol. 157, no. 8, pp. 1410-1418, 2009.
30. F. Q. Cunha, S. Poole, B. B. Lorenzetti, and S. H. Ferreira, "The pivotal role of tumour necrosis factor in the development of inflammatory hyperalgesia, " British Journal of Pharmacology, vol. 107, no. 3, pp. 660-664, 1992.
31. S. Ghosh, M. J. May, and E. B. Kopp, "NF-KappaB and rel proteins: evolutionarily conserved mediators of immune responses, " Annual Review of Immunology, vol. 16, pp. 225-260, 1998.
32. A. S. Baldwin Jr., "Series introduction: The transcription factor NF-kappaB and human disease, "The Journal of Clinical Investigation, vol. 107, no. 1, pp. 3-6, 2001.
33. E. B. Kopp and S. Ghosh, "NF-KappaB and rel proteins in innate immunity, " Advances in Immunology, vol. 58, pp. 1-27, 1995.
34. J. M. Braganza, S. H. Lee, R. F. McCloy, and M. J. McMahon, "Chronic pancreatitis, " The Lancet, vol. 377, no. 9772, pp. 1184- 1197, 2011.
35. E. C. Thrower, F. S. Gorelick, and S. Z. Husain, "Molecular and cellular mechanisms of pancreatic injury, " Current Opinion in Gastroenterology, vol. 26, no. 5, pp. 484-489, 2010.
36. F. Polito, A. Bitto, N. Irrera et al., "Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis, " The British Journal of Pharmacology, vol. 161, no. 5, pp. 1002-1011, 2010.
37. S. Messina, A. Bitto, M. Aguennouz et al., "Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone, " Experimental Neurology, vol. 220, no. 2, pp. 349-358, 2009.
38. T. Iannitti, S. Capone, D. Feder, and B. Palmieri, "Clinical use of immunosuppressants in duchenne muscular dystrophy, " Journal of Clinical Neuromuscular Disease, vol. 12, no. 1, pp. 1-21, 2010.
39. S. Messina, D. Altavilla, M. Aguennouz et al., "Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice, " The American Journal of Pathology, vol. 168, no. 3, pp. 918-926, 2006.
40. D. Altavilla, L. Minutoli, F. Polito et al., "Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia, " British Journal of Pharmacology, vol. 167, no. 1, pp. 95-108, 2012.
41. B. P. Burnett, S. Silva, M. H. Mesches, S. Wilson, and Q. Jia, "Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu, " Journal of Food Biochemistry, vol. 31, no. 6, pp. 797-825, 2007.
42. M. Yimam, Y. Zhao, W. Ma, Q. Jia, S. Do, and J. Shin, "90-Day oral toxicity study of UP446, a combination of defined extracts of Scutellaria baicalensis and Acacia catechu, in rats, " Food and Chemical Toxicology, vol. 48, no. 5, pp. 1202-1209, 2010.
43. R. Levy, A. Khokhlov, S. Kopenkin et al., "Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee-a subset analysis, " Advances in Therapy, vol. 27, no. 12, pp. 953-962, 2010.
44. R. M. Levy, A. Khokhlov, S. Kopenkin et al., "Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: A randomized multicenter controlled trial in subjects with osteoarthritis of the knee, " Advances in Therapy, vol. 27, no. 10, pp. 731-742, 2010.
45. L. Pillai, R. M. Levy, M. Yimam, Y. Zhao, Q. Jia, and B.P.Burnett, "Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies, " Advances inTherapy, vol. 27, no. 6, pp. 400-411, 2010.
46. L. Pillai, B. P. Burnett, and R. M. Levy, "GOAL: Multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin, " Current Medical Research and Opinion, vol. 26, no. 5, pp. 1055- 1063, 2010.